Meatable Acquires Uncommon Bio’s Cultivated Meat Platform

Meatable, a cultivated meat company based in the Netherlands, has acquired the cultivated meat platform of UK biotech company Uncommon Bio. This acquisition includes key technology, intellectual property assets, high-performing cell lines, and expert staff. Meatable claims to now operate the only true multi-platform cultivated meat technology offering, integrating Uncommon Bio’s non-GMO mRNA reprogramming and saRNA differentiation technologies with its patented opti-ox system. This integration will accelerate time to market, navigate regulatory pathways worldwide, and adapt to consumer and cultural preferences.

With this acquisition, Meatable is poised to expand rapidly across species, markets, and consumer segments. The company aims to develop cultivated chicken, lamb, and high-flavor breeds, leveraging Uncommon’s technology. Meatable is also forming partnerships across the supply chain to complement traditional livestock producers. This acquisition is seen as a strategic step in setting a new standard for cultivated meat production and ensuring a stable, secure, and future-proof supply of species like pork, beef, lamb, and poultry on a global scale.